Repurposing Penfluridol in Combination with Temozolomide for the Treatment of Glioblastoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyungsin | - |
dc.contributor.author | Chong, Kyuha | - |
dc.contributor.author | Ryu, Byung-Kyu | - |
dc.contributor.author | Park, Kyung-Jae | - |
dc.contributor.author | Yu, Mi Ok | - |
dc.contributor.author | Lee, Jihye | - |
dc.contributor.author | Chung, Seok | - |
dc.contributor.author | Choi, Seongkyun | - |
dc.contributor.author | Park, Myung-Jin | - |
dc.contributor.author | Chung, Yong-Gu | - |
dc.contributor.author | Kang, Shin-Hyuk | - |
dc.date.accessioned | 2021-09-01T08:16:47Z | - |
dc.date.available | 2021-09-01T08:16:47Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2019-09 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/63407 | - |
dc.description.abstract | Despite the presence of aggressive treatment strategies, glioblastoma remains intractable, warranting a novel therapeutic modality. An oral antipsychotic agent, penflurido (PFD), used for schizophrenia treatment, has shown an antitumor effect on various types of cancer cells. As glioma sphere-forming cells (GSCs) are known to mediate drug resistance in glioblastoma, and considering that antipsychotics can easily penetrate the blood-brain barrier, we investigated the antitumor effect of PFD on patient-derived GSCs. Using five GSCs, we found that PFD exerts an antiproliferative effect in a time- and dose-dependent manner. At IC50, spheroid size and second-generation spheroid formation were significantly suppressed. Stemness factors, SOX2 and OCT4, were decreased. PFD treatment reduced cancer cell migration and invasion by reducing the Integrin alpha 6 and uPAR levels and suppression of the expression of epithelial-to-mesenchymal transition (EMT) factors, vimentin and Zeb1. GLI1 was found to be involved in PFD-induced EMT inhibition. Furthermore, combinatorial treatment of PFD with temozolomide (TMZ) significantly suppressed tumor growth and prolonged survival in vivo. Immunostaining revealed decreased expression of GLI1, SOX2, and vimentin in the PFD treatment group but not in the TMZ-only treatment group. Therefore, PFD can be effectively repurposed for the treatment of glioblastoma by combining it with TMZ. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.subject | ANTIPSYCHOTIC-DRUGS | - |
dc.subject | TUMOR-GROWTH | - |
dc.subject | STEM-CELL | - |
dc.subject | ADJUVANT TEMOZOLOMIDE | - |
dc.subject | CANCER | - |
dc.subject | SCHIZOPHRENIA | - |
dc.subject | RADIOTHERAPY | - |
dc.subject | BEVACIZUMAB | - |
dc.subject | CONCOMITANT | - |
dc.subject | INHIBITION | - |
dc.title | Repurposing Penfluridol in Combination with Temozolomide for the Treatment of Glioblastoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Chong, Kyuha | - |
dc.contributor.affiliatedAuthor | Park, Kyung-Jae | - |
dc.contributor.affiliatedAuthor | Chung, Seok | - |
dc.contributor.affiliatedAuthor | Chung, Yong-Gu | - |
dc.contributor.affiliatedAuthor | Kang, Shin-Hyuk | - |
dc.identifier.doi | 10.3390/cancers11091310 | - |
dc.identifier.scopusid | 2-s2.0-85073524469 | - |
dc.identifier.wosid | 000489719000095 | - |
dc.identifier.bibliographicCitation | CANCERS, v.11, no.9 | - |
dc.relation.isPartOf | CANCERS | - |
dc.citation.title | CANCERS | - |
dc.citation.volume | 11 | - |
dc.citation.number | 9 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | ANTIPSYCHOTIC-DRUGS | - |
dc.subject.keywordPlus | TUMOR-GROWTH | - |
dc.subject.keywordPlus | STEM-CELL | - |
dc.subject.keywordPlus | ADJUVANT TEMOZOLOMIDE | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | SCHIZOPHRENIA | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordPlus | BEVACIZUMAB | - |
dc.subject.keywordPlus | CONCOMITANT | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordAuthor | penfluridol | - |
dc.subject.keywordAuthor | sphere forming cell | - |
dc.subject.keywordAuthor | tumor growth | - |
dc.subject.keywordAuthor | temozolomide | - |
dc.subject.keywordAuthor | glioblastoma | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.